Introduction: Marginal zone lymphoma (MZL) is an indolent type of non-Hodgkin that develops through pathological B cell receptor signaling. Orelabrutinib, a new-generation oral small molecule Bruton’s tyrosine kinase (BTK) inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Methods: Previously treated r/r patients received orelabrutinib 150 mg once daily phase 2, multicenter, si...